Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
337.02
-6.32 (-1.84%)
Aug 20, 2026, 4:00 PM EDT - Market closed
Krystal Biotech Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Krystal Biotech stock has a consensus rating of "Strong Buy" and an average price target of $382.86. The average 1-year stock price forecast is 13.60% higher than the current stock price, while the lowest is $284 (-15.73%) and the highest is $474 (+40.64%).
Price Target: $382.86 (+13.60%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Krystal Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 10 | 9 | 9 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst RBC Capital No rating | RBC Capital | Buy Initiates $400 | Buy | Initiates | $400 | +18.69% | Aug 14, 2026 |
| Wolfe Research | Wolfe Research | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 12, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $396 → $392 | Buy | Reiterates | $396 → $392 | +16.31% | Aug 4, 2026 |
| Citi | Citi | Buy Maintains $378 → $386 | Buy | Maintains | $378 → $386 | +14.53% | Aug 4, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $403 | Buy | Maintains | $403 | +19.58% | Aug 4, 2026 |
Financial Forecast
Revenue This Year
512.61M
from 389.13M
Increased by 31.73%
Revenue Next Year
654.56M
from 512.61M
Increased by 27.69%
EPS This Year
7.87
from 6.84
Increased by 14.99%
EPS Next Year
9.40
from 7.87
Increased by 19.49%
EPS and Forward PE are based on non-GAAP adjusted numbers.